Evaluation of the Performance of a New Rapid Bacteremia Test in the Intensive Care Patient - Trial NCT06241248
Access comprehensive clinical trial information for NCT06241248 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Bordeaux and is currently Not yet recruiting. The study focuses on Sepsis. Target enrollment is 110 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital, Bordeaux
Timeline & Enrollment
N/A
Apr 01, 2024
May 01, 2025
Primary Outcome
Comparison between OCEAN test and gold standard
Summary
Sepsis is a serious health problem with a very high mortality in the ICU. The most important
 treatment for sepsis is the fastest possible antibiotic therapy. The identification of the
 pathogen responsible for sepsis is essential to propose an appropriate antibiotic treatment.
 However, the diagnosis of bacteremia by blood culture requires an average delay of 48 to 72
 hours. The new test proposed by OCEAN Dx makes it possible to identify a bacteremia in a few
 hours. The main objective of the study is to evaluate the performance of the rapid
 identification test for bacteremia proposed by OCEAN Dx compared to a classic diagnostic
 strategy using blood cultures.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06241248
Non-Device Trial